Updated Protein-based COVID-19 Vaccine Available to UK Private Healthcare Providers

Novavax Inc. recently announced its Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) became available to pharmacies across the United Kingdom (U.K.) for private healthcare providers to offer an updated protein-based non-mRNA option as part of the 2024 vaccination season.

On April 18, 2024, Novavax stated in a press release, Today is an important milestone for our organization. It demonstrates our commitment to deliver an updated protein-based COVID-19 vaccine as we evolve into an endemic market.

It also underscores our place as a long-term partner to public health.

We believe a diverse vaccine portfolio and broader access can be vital in protecting communities in the U.K. and elsewhere. 

Our participation in the U.K. private market follows the receipt of a Wholesale Dealers License from the U.K. Medicines and Healthcare Products Regulatory Agency and the U.K. Health Security Agency’s latest Green Book update in February 2024 includes our updated COVID-19 vaccine for active immunization to prevent COVID-19 in individuals aged 12 and older.